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Risk assessment models strive to predict risks to humans from toxic agents. Safety factors and assumptions are incorporated into these models to
allow a margin of error. In the case of cancer, substantial evidence shows that the carcinogenic process is a multistage process driven by the inter-
action of exogenous carcinogenic exposures, genetic traits, and other endogenous factors. Current risk assessment models fail to consider genetic
predispositions that make people more sensitive or resistant to exogenous exposures and endogenous processes. Several cytochrome P450
enzymes, responsible for metabolically activating carcinogens and medications, express wide interindividual variation whose genetic coding has
now been identified as polymorphic and linked to cancer risk. For example, a restriction fragment-length polymorphism for cytochrome P4501A1,
which metabolizes polycyclic aromatic hydrocarbons, and cytochrome P4502E1, which metabolizes N-nitrosamines and benzene, is linked to lung
cancer risk. Cytochrome P4502D6, responsible for metabolizing many clinically important medications, also is linked to lung cancer risk. The fre-
quency for each of these genetic polymorphisms vary among different ethnic and racial groups. In addition to inherited factors for the detection of
sensitive populations, determining the biologically effective doses for carcinogenic exposures also should quantitatively and qualitatively enhance
the risk assessment process. Levels of carcinogen-DNA adducts reflect the net effect of exposure, absorption, metabolic activation, detoxification,
and DNA repair. These effects are genetically predetermined, inducibility notwithstanding. The combination of adduct and genotyping assays pro-
vide an assessment of risk that reflects recent exogenous exposure as well as one's lifetime ability to activate and detoxify carcinogens. -Environ
Health Perspect 102(Suppl 1 1):81-87 (1994)
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Introduction
The protection of populations from car-
cinogenic agents (and other toxins) gener-
ally requires a risk assessment process before
regulation or remedial action. A formal risk
assessment involves several steps including a
hazard assessment, dose-response assess-
ment, exposure assessment, and risk charac-
terization (1). In general, data from
scientific studies are extrapolated to human
experience through mathematical modeling
that identifies a level ofchemical exposure
that might predictably result in a specific
number ofadverse outcomes (e.g., clinical
cancer). Mathematical modeling, however,
essentially is a substitute for scientifically
determined data and is sometimes accepted,
for a variety of reasons, without adequate
validation. Many risk assessment steps
incorporate untested assumptions or have
methodological problems such as using
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premises that are not consistent with
known scientific data (e.g., using multistage
models with the number ofstages less than
that determined from human cancer stud-
ies). Moreover, a fundamental limitation of
risk assessment is that it usually examines
risk for populations rather than for individ-
uals, thereby not considering interindivid-
ual variation in response to xenobiotic
exposure. Individuals or groups ofindividu-
als (e.g., families or ethnicity) might be
more sensitive or resistant to particular
exposures based on xenobiotic activation or
detoxification, DNA repair, genetic struc-
ture, etc. Thus, the risk assessment process
that does not include the interaction ofthe
environment with interindividual capacities
will become increasingly limited.
Carcinogenesis is a multistage process of
normal growth, differentiation, and devel-
opment gone awry (2,3). It is driven by
spontaneous and carcinogen-induced
genetic and epigenetic events. Carcinogenic
agents initiate the process by causing DNA
mutations and altered gene expression.
These genetic effects, in concert with addi-
tional carcinogen exposure and other
genetic or epigenetic effects, lead to tumor
promotion. Through these stages, cells have
selective reproductive and clonal expansion
capabilities. Progressive phenotypic changes
and genomic instability occur (aneuploidy,
mutations, and gene amplification). These
genetic changes enhance the probability of
initiated cells transforming into a malig-
nancy; the odds ofwhich are increased dur-
ing repeated rounds of cell replication.
Angiogenesis allows for a tumor to grow
beyond 1 or 2 mm in size. Ultimately,
tumor cells can disseminate through vessels
invading distant tissues and establishing
metastatic colonies. Each ofthese steps can
be directly affected by carcinogen exposure.
The response to these exposures, however,
can vary from individual to individual (4).
Note also that the current concepts ofiniti-
ation, promotion, genetic, and epigenetic
effects have been conceptually important
but are now considered simplistic and not
consistent with current human carcinogen-
esis models.
The role ofprotooncogenes and tumor
suppressor genes has become increasingly
apparent in the multistage model of car-
cinogenesis (2). Both are important to the
regulatory mechanisms ofgrowth, cell cycle
control and terminal differentiation (2,5).
Activation ofprotooncogenes enhance the
probability of neoplastic transformation,
which can either be an early or late event.
Tumor suppressor genes code for products
that, unlike protooncogenes, enhance the
probability of neoplastic transformation
when their activity is lost. For example, the
p53 tumor suppressor gene, located on
chromosome 17, is the most commonly
altered suppressor gene among all tumors
so far studied (6). Single base substitutions
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can result in loss offunction or production
ofp53 proteins that either interfere with
normal function or otherwise directly
enhance neoplastic transformation (7).
The multistage process ofcarcinogenesis
is best exemplified by a model ofhuman
colorectal tumorigenesis described by
Fearon and others (8). In the early stages,
loss or inactivation ofAPC (9,10) and
MCCgenes (11), hypomethylation and
genomic instability accompanies the pheno-
typic appearance of an adenoma. More
advanced tumors involve oncogenes and
tumor suppressor genes, typically not
observed in early adenomas. The combined
events are more important than the actual
order in which they occur. The genetic
abnormalities include Ki-ras mutations on
chromosome 12, mutation ofp53 tumor
suppressor genes on chromosome 17, and a
deletion of DCC, the putative tumor sup-
pressor gene on chromosome 18q that may
be involved in cell-to-cell adhesion and pos-
sibly metastasis. Other allelic losses can
occur in any of the other chromosomes.
Thus, it appears that at least six genetic
events occur in the development ofcolorec-
tal carcinoma.
The method by which carcinogenic
agents affect DNA and produce mutational
spectra is varied. Chemical carcinogens gen-
erally undergo metabolic activation to elec-
trophilic intermediates that form DNA
adducts through covalent binding (12).
Promutagenic adducts can then cause muta-
tions through mispairing or base substitu-
tions during DNAsynthesis. The bindingof
carcinogens to DNA nucleotides is appar-
ently nonrandom (13-15) and has been
shown to affect protooncogenes and tumor
suppressor genes. Among the best studied
examples ofmetabolic activation is the epox-
idation reactions ofpolycyclic aromatic
hydrocarbons (PAH), of which
benzo[a]pyrene (BP) is one example
(16,17). These compounds are composed of
fused benzene rings that are essentially water
insoluble but readily absorbed through the
lungs and gastrointestinal tract. They are
commonly found as combustion products of
fossil fuels (e.g., coal, diesel exhaust) and
vegetable matter. Consequently, PAHs
occur as environmental pollutants. BP
becomes metabolically activated in a phase 1
reaction by forming a reactive diol epoxide
that can covalently bind to DNA-forming
adducts. Initially, cytochrome P450
(CYP)lAl and epoxide hydroxylase catalyze
the conversion of BP to a dihydrodiol.
Then, CYP3A4 converts this product to a
diol-epoxide (i.e., BP-7,8-diol-9,10-epoxide)
that is the reactive form. However, along
this pathway, intermediates might be
removed via conjugation (e.g., glutathione
transferase), further oxidation, or reduction.
These metabolites can then be excreted in
urine or feces. It is worthwhile noting that
the activity ofseveral enzymes involved in
these activation and detoxification processes,
as well as DNA repair, varies markedly in
individuals, so that reactions lending to the
formation and removal of BP-related
adducts and mutations can occur at higher
or lower rates (4).
On a molecular basis, cells possess the
ability to repair DNA damage (18). Smaller
alkyl adducts can be excised while larger
adducts require the excision ofseveral bases.
An extensively studied repair enzyme is the
06-alkylguanine-DNA-alkyltransferase
(19). This enzyme'repairs damage from
alkylating agents such as tobacco-specific
nitrosamines and other N-nitrosocom-
pounds. It is a suicide protein in that it
transfers the alkyl group to itself and
becomes inactivated. Cell cytotoxicity and
tumor cell resistance are negatively corre-
lated with the levels ofthis enzyme (20),
and levels vary within organs and among
people (21,22). PAH-DNA adducts can be
repaired by a nucleotide excision pathway.
A unimodal distribution ofrepair rates of
benzo[a]pyrene diol-epoxide DNA adducts
has been observed using human lympho-
cytes in vitro (23). The interindividual vari-
ation was substantially greater than the
intraindividual variation, which suggests a
role for inherited factors.
GeneticPredispositions to Cancer
Interindividual variation in response to
xenobiotics and their potential carcinogenic
effects is mediated by inherited predisposi-
tions (Table 1). Family cancer syndromes,
the most evident expression ofinherited pre-
dispositions, can lead to up to a 1000-fold
increased risk ofcancer in family members
(24). However, most individuals do not
have such an obvious genetic predisposition,
and host susceptibility relating to a specific
gene is less obvious because these mutations
as risk factors are barely detectable above
background. Current studies show that
these factors are more common in some
family, ethnic, and racial groups.
CYPlAI has been extensively studied in
the metabolism of PAHs. Activity of
CYPlAl varies in lung tissues from differ-
ent persons (25,26), which is an inheritable
trait (27) but also can be induced upon
exposure to agents such as tobacco smoke
(28). Inducability varies among individuals
and is notably higher in lung cancer
patients than in noncancer controls
(29,30). Levels ofaryl hydrocarbon hydrox-
ylase activity also have been correlated with
levels ofDNA adducts (31) and with prog-
nosis in lung cancer (32). Recently, a
restriction fragment length polymorphism
has been described, using Msp 1 restriction
digestion, that is reported to correlate with
lung cancer risk in a Japanese cohort (33)
and also found to be in genetic disequilib-
rium with a mutation in the catatylic region
ofthe enzyme (34). Evidence suggests that
the mutation results in increased metabolic
activation (K Kawajiri, personal communi-
cation) and the polymorphism was corre-
lated with a 3-fold increase in lung cancer
risk (33). Further study showed that the
effect was greatest in persons with squa-
mous cell cancer and in persons with the
least amount of tobacco smoking history
(35). This latter point indicates that the
effect ofthis polymorphism is strongest in
persons with less carcinogenic exposure.
The National Cancer Institute-
University of Maryland (NCI-UMD)
Case-Control Study investigated lung can-
cer patients and controls (pulmonary dis-
ease patients and nonlung cancer patients)
for inherited predispositions to lung can-
cer. The control groups had similar age and
smoking status. The Msp 1 polymorphism
ofCYPlAI and lung cancer risk was stud-
ied-in 101 persons enrolled in this study,
but no association was found with either
lung cancer risk or histological lung cancer
type. However, there was a statistically
significant difference in allelic frequencies
for African Americans versus Caucasians.
This suggests that on the basis of the
Table 1. Examples of interindividual variation in response to xenobiotics and cancer risk or prognosis.
Response Example Human cancertype
Metabolic activation Cytochrome P4501A1 Lung (33)
Cytochrome P4502D6 Lung (37,38)
Cytochrome P4502E1 Lung (48)
N-Acetyltransferase Bladder/colon (81,82)
Detoxification Glutathione Stransferase Ml Lung/stomach/colon (81,82)
DNA repair Excision of UVdamage Skin (83)
Protooncogene HRAS-1 Lung (84,85)
L-myc Lung/gastric/sarcoma (86,87)
Tumor suppressor gene p53 Li-Fraumeni syndrome (88)
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Japanese data, African Americans would be
more sensitive to lung cancer. Separate
analysis by race did not reveal an associa-
tion with lung cancer risk although the
numbers of each group substantially lim-
ited the statistical power of the study.
Thus, the study numbers are currently
being increased. In a separate Norwegian
study (36), no association with the Msp 1
RFLP and lung cancer was found.
Importantly, this study was severely hin-
dered by not utilizing age- and smoking-
matched controls that can result in falsely
negative findings. The frequency of the
exon 7 mutation in cancer patients and
matched controls, and its linkage with the
Msp 1 RFLP, in American and European
ethnic groups is now required.
The study ofthe cytochrome P4502D6
(CYP2D6, also know as the debrisoquine
polymorphism) is among the best examples
ofinheritable interindividual differences in
metabolism. This enzyme is responsible for
metabolism ofseveral medications includ-
ing tricyclic antidepressants, beta-blocking
antihypertensives, and debrisoquine. Poor
metabolizers are at risk of adverse drug
reactions. In a cohort of smokers in
London, England, a 4-fold higher risk of
lung cancer was associated with the exten-
sive metabolic phenotype (37). This associ-
ation has been confirmed in the
NCI-UMD lung cancer case-control study
with an odds ratio of six (38). The exten-
sive metabolic phenotype also has been
shown to have an interactive effect with
occupational exposures to asbestos and
PAHs (39).
Genotyping methods for CYP2D6have
been sought to avoid the requirement for
time-consuming urinary phenotyping and
the attendant hypothetical risks of drug
administration. These methods also would
clarify whether the association with lung
cancer might be a result of a cancer effect
on the phenotypic expression rather than
an inherited predisposition that predated
the development ofcancer. An Xba 1 RFLP
was described (40) where identifiable alleles
were associated with the poor metabolizer
phenotype. However, it was soon found
that the EcoR 1 RFLP only correctly pre-
dicted one-third ofpoor metabolizers (41).
Since then, it was found that most of the
poor metabolizer phenotypes could be
explained by specific mutations in
CYP2D6(42). These and other mutations
have now been designated as A, B, C, and
D mutations (Table 2) (40,42-44).
Two polymerase chain reaction (PCR)
assays have been published to determine the
A and B mnutations in CYP2D6 (42,45).
Table 2. Cytochrome P4502D6 genotypes and phenotypes (42,44).
Type Xba IRFLPa Location Description Associated phenotype
Wild-type 29 Kb NAb Wild-type sequence Extensive
A 29 Kb Exon 5 Nucleotide deletion (2737A) Poor
B 29 Kb Exon 3 Splice site defect (1934 G-T) Poor
C 29 Kb Exon 5 Nucleotide deletions (2702-2706 AGA) Extensive
D 11.5 Kb NA Deletion of cytochrome P4502D6 Poor
aResults of Southern blot analysis yielding fragment length shown. bNot applicable.
The D mutation is identified with theXba 1
restriction digest and Southern blotting
(40). The A and B mutations can be
identified by using a PCR mismatch assay
where primers differ only by the 3-ft base
that matches with either the wild-type base
or the mutant base (42). The assay begins
with a first step that uses primers specific
only for CYP2D6and not the psuedogenes
CYP2D7and CYP2D8, which are otherwise
almost 95% homologous. The second step
uses the mismatch primers. The assay
requires careful validation to ensure correct
priming, sensitivity, and specificity. This
method can reportedly characterize over
95% ofmetabolic phenotypes in large num-
bers of Europeans. The second method
takes advantage ofa BstN1 restriction site at
the B mutation and uses an altered primer
that introduces a Dra 1 restriction site at the
A mutation (45) (R Wolf, personal com-
munication). In our laboratory, we have
been genotyping individuals using a com-
bined approach that uses the BstN 1 digest
for the B mutation with the primers previ-
ously identified as not significantly homolo-
gous (42) and the mismatch assay for the A
mutation. We have found that the fre-
quency ofpoor metabolizers in Caucasians
by genotyping was statistically significantly
higher than in African-Americans, suggest-
ing an inherited predisposition to lung can-
cer in African Americans (P Shields,
unpublished results).
Thus far, the mechanistic relationship of
CYP2D6activity to lung cancer remains
unknown. The only known carcinogenic
substrate identified for CYP2D6 is 4-
(methyl-nitrosamino)-1-(3-pyridyl)- 1-
butanone (NNK) but not other
tobacco-specific nitrosamines that have been
tested (46). Thus, the lung cancer associa-
tion might relate to altered substrate
specificityofthe enzyme in extensive metab-
olizers not studied, unidentified carcino-
genic substrates, or a gene that is in linkage
disequilibrium with another gene related to
cancer risk.
CYP2E1 is responsible for metabolizing
a number ofpotential human carcinogens
including benzene and N-nitrosamines.
Several genetic polymorphisms have been
identified (47,48). One polymorphism
includes two distinct base substitutions in
the same area, which are in genetic disequi-
librium so that either one can be studied
(47). This area is involved in transcription
regulation and preliminary studies indicate
that one type allows for increased expres-
sion of the chloramphenicol acetyl trans-
ferase gene in transfected HepG 2 cells.
The frequency ofthe polymorphic alleles is
different in Japanese and Americans (S
Kato, personal communication, 1992).
Whether this polymorphism has a relation-
ship to cancer risk is currently under study.
The other polymorphism is at Dral restric-
tion enzyme site in intron 6 (M Watanabe,
personal communication). While its bio-
logical significance is unknown, it has been
reported that the distribution ofgenotypes
is significantly different in lung cancer
cases and controls (48).
MolecularDosimetry-Identifyinga
Combined Carcinogen Exposure and
Susceptibility
One indicator for the net effect of exoge-
nous carcinogen exposure and inherited
traits for absorption, metabolism, and
DNA repair is the carcinogen-DNA
adduct. Measurement of adducts can be
useful for estimating a biologically effective
dose of a carcinogen and the risk for fixed
mutations. A variety ofassays are available
to identify carcinogen-DNA and protein
adducts. Enzyme immunoassays (49-58),
32P-postlabeling and nucleotide chro-
matography (59-61), fluorescence spec-
troscopy (62), synchronous fluorescence
spectroscopy (SFS) (63-66), gas chro-
matography and mass spectroscopy
(GC/MS) (66,67), and electrochemical
detection (68) have been applied to the
analysis ofhuman lung samples or a surro-
gate tissue or cell population.
Central to the studies of DNA adducts
is the development ofsensitive and specific
assays that are required to detect femtomole
and attomole levels of adducts in micro-
gram amounts of DNA. Current methods
are challenged because of the complexity
and multitude of possible exposures in
human tissues. The specificity of adduct
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assays, and therefore their quantitative relia-
bility, can be enhanced by using micro-
preparative techniques. For example,
subjecting enzymatically digested lung
DNA to high-pressure liquid chromatogra-
phy (HPLC) followed by the 32P-postlabel-
ing assay, which relies on three different
separations (HPLC and two-dimensional
thin-layer chromatography) can detect N-
nitrosamine-related alkyl adducts such as
od-methyl-2'-deoxyguanosine (69), 06-
ethyldeoxyguanosine (dSethyldG) (69), N-
7-methyldeoxyguanosine (N7methyldG)
(70) and N-7-ethyldeoxyguanosine (S Kato,
personal communication) at levels as low as
one adduct in 107 2'-deoxyguanosine
residues. Other laboratories have used
HPLC after 32P-postlabeling (71).
Immunoaffinity chromatography also has
been combined with 32P-postlabeling assay
to identify 06-methyldeoxyguanosine (D
Cooper, personal communication) and
polycyclic aromatic hydrocarbons (P
Shields, unpublished data). In both cases,
the level of detection was at least one
adduct in I07 unmodified deoxyguanosine.
Another feature ofassays that are dependent
upon micropreparative techniques is that
they are developed using authentically syn-
thesized adduct standards, use internal stan-
dards, and quantitation based upon
calibration curves.
Organ tissue selection, multiple sources
of exposures, and other confounders
impact upon study design and results. It
would be optimal to use easily obtainable
body fluids such as blood or urine for risk
assessment. However, it remains to be
established ifblood testing will be a reliable
surrogate for other tissues. For example,
some data suggest that the determination
of PAH adducts in peripheral lymphocyte
DNA reflects dietary rather than inhala-
tional exposures (72,73). We also will need
to consider cellular differences in life-span
(lymphocytes and red blood cells survive
longer than granulocytes), DNA repair
capacity, and metabolic capacity. It has
been reported that the initial adduction of
lymphocytes and granulocytes is similar
but that adduct levels are more persistent
in the latter (74). Our laboratory has used
lymphocytes (49-51,63) while others have
studied total white blood cells (predomi-
nantly granulocytes) (54,72). Oral mucosal
cells are another relatively noninvasive
source of DNA and can allow for the
detection of several types of adducts
(57,60).
Multiple types of adducts have been
observed in individual lung samples,
confirming the complex nature ofcarcino-
Table 3. Genetic polymorphisms and ethnicity.
Polymorphism Populations compared At riska
Cytochrome P4501Al African-Americans vs Caucasians African-Americans
Cytochrome P4502D6 African-Americans vs Caucasians African-Americans
Cytochrome P4502E1 Americans vs Japanese Japanese
L-mycprotooncogene African-Americans vs Caucasians African-Americans
H-rasprotooncogene African-Americans vs Caucasians African-Americans
p53 African-Americans vs Caucasians NAb
NA, not applicable. "Population found to have higher frequency at alleles associated with lung cancer. aAllele not
associated with cancer risk but statistically varies among compared populations.
genic exposures (75). Small alkyl adducts,
polycyclic aromatic hydrocarbons adducts,
and aromatic amines have been identified.
Improved micropreparative techniques
have led to the unambiguous identification
of specific polycyclic aromatic hydrocar-
bons adducts in human lung (63,66). This
finding has now been confirmed by com-
bining immunoaffinity chromatography
with the 32P-postlabeling assay (P Shields,
unpublished data).
Exposures to PAH compounds are asso-
ciated with an increased riskoflung cancer.
Industrial pollution, fossil fuels, and
tobacco smoke account for the major envi-
ronmental sources. Dietary exposures also
commonly occur because ofovercooked or
charcoal-broiled meats. Adduct levels have
been correlated with exposure in coke oven
workers (54,59,76), tobacco consumption
(67), and urban versus rural residence
(77), but decreases during vacation from
occupational sources (51). Seasonal varia-
tion in adduct levels also has been observed
(78). Some studies have not found correla-
tions with tobacco consumption but this
may be because of other sources of expo-
sure (e.g., diet).
Conclusions
The current data indicate that several
inherited genetic traits are associated with
cancer risk. Frequencies of these also vary
among ethnic populations (Table 3). The
interaction ofenvironmental exposures and
metabolic capacities suggests that current
risk assessment models need to be biologi-
cally based and consider the variation in
sensitivity among individuals. The multi-
stage model of carcinogenesis further sug-
gests that single low-dose exposures and
most genetic traits will likely not be
sufficiently strong by themselves to drive
the carcinogenic process. Thus, risk assess-
ment models need to incorporate interac-
tive effects (chemical, radiation, viral, and
physical agents interacting with each other
and with host factors).
The use of genotyping assays and
adduct determinations require rigorous
field testing in carefully designed studies.
Genotyping assays need to be studied in
both case-control studies and prospective
studies where confounding variables are
carefully considered (e.g., tobacco use or
multiple sources of exposure). Genotyping
assays are preferable to phenotyping assays
because they cannot be altered by the pres-
ence of disease. For adduct assays, the
importance ofthe development and valida-
tion phases cannot be overstated and need
to be meticulously performed prior to their
use in large field trials.
NOTE ADDED IN PROOF: Since the
preparation ofthis manuscript in 1992, all
ofthe data cited as personal communication
have now been published. There also are a
number of more recent reviews. New data
has identified several examples ofgene-envi-
ronment interactions where the effects of
metabolizing polymorphisms vary depend-
ing on exposure, further impacting upon
riskassessment procedures and outcomes.
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